Can progesterone only pills (POP) be used to treat premenstrual syndrome (PMS) in breastfeeding women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Progesterone-Only Pills for Premenstrual Syndrome in Breastfeeding Women

Progesterone-only pills (POPs) are safe for breastfeeding women and can be started immediately postpartum, but they are not effective for treating premenstrual syndrome (PMS). 1, 2, 3

Safety of POPs During Breastfeeding

POPs are the safest oral contraceptive option for breastfeeding mothers and pose no restrictions on use:

  • POPs can be initiated immediately postpartum without concerns about milk production or infant safety. 1, 4, 5
  • No backup contraception is needed if POPs are started within 6 months postpartum while amenorrheic and fully/nearly fully breastfeeding (≥85% of feeds are breastfeeds). 1, 5
  • If started >21 days postpartum without return of menses, use backup contraception for 7 days. 1, 5
  • POPs are classified as Category 1 (no restriction) or Category 2 (advantages generally outweigh risks) for breastfeeding women at all postpartum time points. 6

Ineffectiveness of Progesterone for PMS Treatment

The evidence consistently demonstrates that progesterone does not effectively treat PMS:

  • A large randomized, placebo-controlled, double-blind crossover study of 168 women found that progesterone suppositories (400 mg and 800 mg doses) did not significantly improve premenstrual symptoms compared to placebo on any measure, including daily symptom reports, clinician evaluation, or patient global reports. 2
  • A Cochrane systematic review concluded that trials did not show progesterone is an effective treatment for PMS, nor that it is not—the evidence is simply insufficient and of poor quality. 3
  • No symptom cluster or individual PMS symptom differed significantly between progesterone and placebo treatment. 2

Clinical Implications

For a breastfeeding woman seeking both contraception and PMS relief:

  • Use POPs for contraception without hesitation, as they are safe and effective for breastfeeding mothers. 1, 4, 5
  • Do not prescribe POPs with the expectation of PMS symptom improvement, as progesterone has not demonstrated efficacy for this indication. 2, 3
  • Consider evidence-based PMS treatments separately: serotonergic antidepressants (SSRIs) have the strongest evidence for PMS symptom reduction, followed by calcium supplements, Vitex agnus castus (chasteberry), and cognitive-behavioral therapies. 7
  • Some oral contraceptives containing both estrogen and progestin have demonstrated efficacy for PMS, but combined hormonal contraceptives should be avoided during breastfeeding, particularly in the first 6 months postpartum (Category 3-4 depending on timing and VTE risk factors). 1, 4, 5

Important Caveats

  • While progesterone theory proposes that PMS results from enhanced progesterone sensitivity following ovulation, treatment with exogenous progesterone has failed to demonstrate clinical benefit. 8, 3
  • The lack of efficacy applies to both oral and vaginally absorbed progesterone formulations. 3
  • For women with prior gestational diabetes, particularly in Latino populations, use POPs with caution during breastfeeding due to a two- to threefold increase in diabetes risk. 1

References

Guideline

Contraception Guidance for Breastfeeding Mothers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Progesterone for premenstrual syndrome.

The Cochrane database of systematic reviews, 2012

Guideline

Contraception and Breastfeeding Guidance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Oral Contraceptives During Breastfeeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Therapeutic management of premenstrual syndrome.

Expert opinion on pharmacotherapy, 2010

Research

Hormonal management of premenstrual syndrome.

Best practice & research. Clinical obstetrics & gynaecology, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.